88 related articles for article (PubMed ID: 38623463)
1. Therapeutic Potential of Targeting Transforming Growth Factor-beta (TGF-β) and Programmed Death-ligand 1 (PD-L1) in Pancreatic Cancer.
Pourali G; Zafari N; Velayati M; Mehrabadi S; Maftooh M; Hassanian SM; Mobarhan MG; Ferns GA; Avan A; Khazaei M
Curr Drug Targets; 2023; 24(17):1335-1345. PubMed ID: 38053355
[TBL] [Abstract][Full Text] [Related]
2. T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer.
Palecki J; Bhasin A; Bernstein A; Mille PJ; Tester WJ; Kelly WK; Zarrabi KK
Cancer Biol Ther; 2024 Dec; 25(1):2356820. PubMed ID: 38801069
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a Trispecific PD-L1 Blocking Antibody That Exhibits EGFR-Conditional 4-1BB Agonist Activity.
Rubio-Pérez L; Frago S; Compte M; Navarro R; Harwood SL; Lázaro-Gorines R; Gómez-Rosel M; Hangiu O; Silva-Pilipich N; Vanrell L; Smerdou C; Álvarez-Vallina L
Antibodies (Basel); 2024 Apr; 13(2):. PubMed ID: 38804302
[TBL] [Abstract][Full Text] [Related]
4. Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy.
Qin X; Ning W; Liu H; Liu X; Luo W; Xia N
Acta Pharm Sin B; 2024 Jun; 14(6):2361-2377. PubMed ID: 38828136
[TBL] [Abstract][Full Text] [Related]
5. Thoracic Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023 with Focus on Perioperative Therapy, Radiotherapy, and Bispecific T-Cell Engagers.
Kemper M; Soltani Germy P; Acker F; Luan J; Griesinger F; Tufman A; Kropf-Sanchen C; Overbeck TR; Bleckmann A; Blasi M
Oncol Res Treat; 2024; 47(6):312-315. PubMed ID: 38574467
[No Abstract] [Full Text] [Related]
6. Facile Access to Branched Multispecific Proteins.
Okon A; Yang J; Giancola JB; Molina OJ; Sayers J; Cheah KM; Li Y; Strieter ER; Raines RT
Bioconjug Chem; 2024 Jun; ():. PubMed ID: 38879814
[TBL] [Abstract][Full Text] [Related]
7. Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy.
Li T; Wang X; Niu M; Wang M; Zhou J; Wu K; Yi M
Front Immunol; 2023; 14():1196970. PubMed ID: 37520520
[TBL] [Abstract][Full Text] [Related]
8. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.
Gulley JL; Schlom J; Barcellos-Hoff MH; Wang XJ; Seoane J; Audhuy F; Lan Y; Dussault I; Moustakas A
Mol Oncol; 2022 Jun; 16(11):2117-2134. PubMed ID: 34854206
[TBL] [Abstract][Full Text] [Related]
9. Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses.
Tapia-Galisteo A; Sánchez-Rodríguez I; Narbona J; Iglesias-Hernández P; Aragón-García S; Jiménez-Reinoso A; Compte M; Khan S; Tsuda T; Chames P; Lacadena J; Álvarez-Vallina L; Sanz L
Oncoimmunology; 2024; 13(1):2338558. PubMed ID: 38623463
[TBL] [Abstract][Full Text] [Related]
10. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
[TBL] [Abstract][Full Text] [Related]
11. Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy.
Niu M; Yi M; Wu Y; Lyu L; He Q; Yang R; Zeng L; Shi J; Zhang J; Zhou P; Zhang T; Mei Q; Chu Q; Wu K
J Hematol Oncol; 2023 Aug; 16(1):94. PubMed ID: 37573354
[TBL] [Abstract][Full Text] [Related]
12. Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer.
Yi M; Wu Y; Niu M; Zhu S; Zhang J; Yan Y; Zhou P; Dai Z; Wu K
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460337
[TBL] [Abstract][Full Text] [Related]
13. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
[TBL] [Abstract][Full Text] [Related]
14. Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression.
Ding Z; Sun S; Wang X; Yang X; Shi W; Huang X; Xie S; Mo F; Hou X; Liu A; Jiang X; Tang Z; Lu X
J Hematol Oncol; 2023 Nov; 16(1):115. PubMed ID: 38031188
[TBL] [Abstract][Full Text] [Related]
15. The present and future of bispecific antibodies for cancer therapy.
Klein C; Brinkmann U; Reichert JM; Kontermann RE
Nat Rev Drug Discov; 2024 Apr; 23(4):301-319. PubMed ID: 38448606
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
